BioNTech lung cancer drug extends survival versus chemotherapy
One daysingle sourceOne outlet reported this, once - no second voice in this corpus.
All 1 reports on Mon, 14 September 2026
What it is about
Who published it, and when
How it spread - 1 original report
Mon, 14 September 2026
1 report- Japan Times11:57first to report
Patients treated with gotistobart lived for a median 18.5 months, compared with 10 months for those given the standard-of-care chemotherapy.